Congenital muscular dystrophy (CMD) is a clinically and genetically heterogeneous group of inherited muscle disorders. In patients, muscle weakness is usually present at or shortly after birth and is progressive in nature. Merosin deficient congenital muscular dystrophy (MDC1A) is a form of CMD caused by a defect in the laminin-α2 gene (LAMA2). Laminin-α2 is an extracellular matrix protein that interacts with the dystrophin-dystroglycan (DGC) complex in membranes providing stability to muscle fibers. In an N-ethyl-N-nitrosourea mutagenesis screen to develop zebrafish models of neuromuscular diseases, we identified a mutant fish that exhibits severe muscular dystrophy early in development. Genetic mapping identified a splice site mutation in the lama2 gene. This splice site is highly conserved in humans and this mutation results in mis-splicing of RNA and a loss of protein function. Homozygous lama2 mutant zebrafish, designated lama2cl501/cl501, exhibited reduced motor function and progressive degeneration of skeletal muscles and died at 8–15 days post fertilization. The skeletal muscles exhibited damaged myosepta and detachment of myofibers in the affected fish. Laminin-α2 deficiency also resulted in growth defects in the brain and eye of the mutant fish. This laminin-α2 deficient mutant fish represents a novel disease model to develop therapies for modulating splicing defects in congenital muscular dystrophies and to restore the muscle function in human patients with CMD.
References
[1]
Mendell JR, Boue DR, Martin PT (2006) The congenital muscular dystrophies: recent advances and molecular insights. Pediatr Dev Pathol 9: 427–443.
[2]
Theodore M, Morava E (2011) Congenital disorders of glycosylation: sweet news. Curr Opin Pediatr 23: 581–587.
Di Blasi C, Bellafiore E, Salih MA, Manzini MC, Moore SA, et al. (2011) Variable disease severity in Saudi Arabian and Sudanese families with c.3924+2 T > C mutation of LAMA2. BMC Res Notes 4: 534.
[5]
Jones KJ, Morgan G, Johnston H, Tobias V, Ouvrier RA, et al. (2001) The expanding phenotype of laminin alpha2 chain (merosin) abnormalities: case series and review. J Med Genet 38: 649–657.
[6]
Helbling-Leclerc A, Zhang X, Topaloglu H, Cruaud C, Tesson F, et al. (1995) Mutations in the laminin alpha 2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy. Nat Genet 11: 216–218.
[7]
Messina S, Bruno C, Moroni I, Pegoraro E, D’Amico A, et al. (2010) Congenital muscular dystrophies with cognitive impairment. A population study. Neurology 75: 898–903.
[8]
Vigliano P, Dassi P, Di Blasi C, Mora M, Jarre L (2009) LAMA2 stop-codon mutation: merosin-deficient congenital muscular dystrophy with occipital polymicrogyria, epilepsy and psychomotor regression. Eur J Paediatr Neurol 13: 72–76.
[9]
Topaloglu H, Talim B, Vignier N, Helbling-Leclerc AH, Yetuk M, et al. (1998) Merosin-deficient congenital muscular dystrophy with severe mental retardation and normal cranial MRI: a report of two siblings. Neuromuscul Disord 8: 169–174.
[10]
Philpot J, Bagnall A, King C, Dubowitz V, Muntoni F (1999) Feeding problems in merosin deficient congenital muscular dystrophy. Arch Dis Child 80: 542–547.
[11]
Miyagoe-Suzuki Y, Nakagawa M, Takeda S (2000) Merosin and congenital muscular dystrophy. Microsc Res Tech 48: 181–191.
[12]
Wewer UM, Engvall E (1996) Merosin/laminin-2 and muscular dystrophy. Neuromuscul Disord 6: 409–418.
[13]
Gupta V, Kawahara G, Gundry SR, Chen AT, Lencer WI, et al. (2011) The zebrafish dag1 mutant: a novel genetic model for dystroglycanopathies. Hum Mol Genet 20: 1712–1725.
[14]
Kuang W, Xu H, Vilquin JT, Engvall E (1999) Activation of the lama2 gene in muscle regeneration: abortive regeneration in laminin alpha2-deficiency. Lab Invest 79: 1601–1613.
[15]
Girgenrath M, Kostek CA, Miller JB (2005) Diseased muscles that lack dystrophin or laminin-alpha2 have altered compositions and proliferation of mononuclear cell populations. BMC Neurol 5: 7.
[16]
Miyagoe Y, Hanaoka K, Nonaka I, Hayasaka M, Nabeshima Y, et al. (1997) Laminin alpha2 chain-null mutant mice by targeted disruption of the Lama2 gene: a new model of merosin (laminin 2)-deficient congenital muscular dystrophy. FEBS Lett 415: 33–39.
[17]
Patton BL, Wang B, Tarumi YS, Seburn KL, Burgess RW (2008) A single point mutation in the LN domain of LAMA2 causes muscular dystrophy and peripheral amyelination. J Cell Sci 121: 1593–1604.
[18]
Xu H, Wu XR, Wewer UM, Engvall E (1994) Murine muscular dystrophy caused by a mutation in the laminin alpha 2 (Lama2) gene. Nat Genet 8: 297–302.
[19]
O’Brien DP, Johnson GC, Liu LA, Guo LT, Engvall E, et al. (2001) Laminin alpha 2 (merosin)-deficient muscular dystrophy and demyelinating neuropathy in two cats. J Neurol Sci 189: 37–43.
[20]
Hall TE, Bryson-Richardson RJ, Berger S, Jacoby AS, Cole NJ, et al. (2007) The zebrafish candyfloss mutant implicates extracellular matrix adhesion failure in laminin alpha2-deficient congenital muscular dystrophy. Proc Natl Acad Sci U S A 104: 7092–7097.
[21]
Zon LI, Peterson RT (2005) In vivo drug discovery in the zebrafish. Nat Rev Drug Discov 4: 35–44.
[22]
Guyon JR, Mosley AN, Zhou Y, O’Brien KF, Sheng X, et al. (2003) The dystrophin associated protein complex in zebrafish. Hum Mol Genet 12: 601–615.
[23]
Lawson ND, Wolfe SA (2011) Forward and reverse genetic approaches for the analysis of vertebrate development in the zebrafish. Dev Cell 21: 48–64.
[24]
Kawahara G, Karpf JA, Myers JA, Alexander MS, Guyon JR, et al. (2011) Drug screening in a zebrafish model of Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 108: 5331–5336.
[25]
Bassett DI, Bryson-Richardson RJ, Daggett DF, Gautier P, Keenan DG, et al. (2003) Dystrophin is required for the formation of stable muscle attachments in the zebrafish embryo. Development 130: 5851–5860.
[26]
Padgett RA, Grabowski PJ, Konarska MM, Seiler S, Sharp PA (1986) Splicing of messenger RNA precursors. Annu Rev Biochem 55: 1119–1150.
[27]
Geranmayeh F, Clement E, Feng LH, Sewry C, Pagan J, et al. (2010) Genotype-phenotype correlation in a large population of muscular dystrophy patients with LAMA2 mutations. Neuromuscul Disord 20: 241–250.
[28]
Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, et al. (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8: 918–928.
[29]
van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, et al. (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357: 2677–2686.
[30]
Osorio FG, Navarro CL, Cadinanos J, Lopez-Mejia IC, Quiros PM, et al. (2011) Splicing-directed therapy in a new mouse model of human accelerated aging. Sci Transl Med 3: 106ra107.
[31]
Hua Y, Vickers TA, Okunola HL, Bennett CF, Krainer AR (2008) Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet 82: 834–848.
[32]
Sumanasekera C, Watt DS, Stamm S (2008) Substances that can change alternative splice-site selection. Biochem Soc Trans 36: 483–490.
[33]
Rooney JE, Knapp JR, Hodges BL, Wuebbles RD, Burkin DJ (2012) Laminin-111 Protein Therapy Reduces Muscle Pathology and Improves Viability of a Mouse Model of Merosin-Deficient Congenital Muscular Dystrophy. Am J Pathol.
[34]
Doe JA, Wuebbles RD, Allred ET, Rooney JE, Elorza M, et al. (2011) Transgenic overexpression of the alpha7 integrin reduces muscle pathology and improves viability in the dy(W) mouse model of merosin-deficient congenital muscular dystrophy type 1A. J Cell Sci 124: 2287–2297.
[35]
Hayashi YK, Tezak Z, Momoi T, Nonaka I, Garcia CA, et al. (2001) Massive muscle cell degeneration in the early stage of merosin-deficient congenital muscular dystrophy. Neuromuscul Disord 11: 350–359.
[36]
Jones KJ, Kim SS, North KN (1998) Abnormalities of dystrophin, the sarcoglycans, and laminin alpha2 in the muscular dystrophies. J Med Genet 35: 379–386.
[37]
Relucio J, Tzvetanova ID, Ao W, Lindquist S, Colognato H (2009) Laminin alters fyn regulatory mechanisms and promotes oligodendrocyte development. J Neurosci 29: 11794–11806.
[38]
Sztal T, Berger S, Currie PD, Hall TE (2011) Characterization of the laminin gene family and evolution in zebrafish. Dev Dyn 240: 422–431.
[39]
Westerfield M (2007) The Zebrafish Book. Eugene: University of Oregon Press.
[40]
Zhou Y, Zon LI (2011) The zon laboratory guide to positional cloning in zebrafish. Methods Cell Biol 104: 287–309.
